Associations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school-age children: a two-way factorial case-control study.
HIV
South Africa
gut microbiota
inflammation
iron deficiency
school-age children
Journal
Journal of human nutrition and dietetics : the official journal of the British Dietetic Association
ISSN: 1365-277X
Titre abrégé: J Hum Nutr Diet
Pays: England
ID NLM: 8904840
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
04
12
2022
accepted:
19
03
2023
medline:
19
5
2023
pubmed:
31
3
2023
entrez:
30
3
2023
Statut:
ppublish
Résumé
Human immunodeficiency virus (HIV) and iron deficiency (ID) affect many African children. Both HIV and iron status interact with gut microbiota composition and related biomarkers. The study's aim was to determine the associations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school-age children. In this two-way factorial case-control study, 8- to 13-year-old children were enrolled into four groups based on their HIV and iron status: (1) With HIV (HIV+) and ID (n = 43), (2) HIV+ and iron-sufficient nonanaemic (n = 41), (3) without HIV (HIV-) and ID (n = 44) and (4) HIV- and iron-sufficient nonanaemic (n = 38). HIV+ children were virally suppressed (<50 HIV RNA copies/ml) on antiretroviral therapy (ART). Microbial composition of faecal samples (16S rRNA sequencing) and markers of gut inflammation (faecal calprotectin) and gut integrity (plasma intestinal fatty acid-binding protein [I-FABP]) were assessed. Faecal calprotectin was higher in ID versus iron-sufficient nonanaemic children (p = 0.007). I-FABP did not significantly differ by HIV or iron status. ART-treated HIV (redundancy analysis [RDA] R In our sample of 8- to 13-year-old virally suppressed HIV+ and HIV- children with or without ID, ID was associated with increased gut inflammation and changes in the relative abundance of specific microbiota. Moreover, in HIV+ children, ID had a cumulative effect that further shifted the gut microbiota to an unfavourable composition.
Sections du résumé
BACKGROUND
Human immunodeficiency virus (HIV) and iron deficiency (ID) affect many African children. Both HIV and iron status interact with gut microbiota composition and related biomarkers. The study's aim was to determine the associations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school-age children.
METHODS
In this two-way factorial case-control study, 8- to 13-year-old children were enrolled into four groups based on their HIV and iron status: (1) With HIV (HIV+) and ID (n = 43), (2) HIV+ and iron-sufficient nonanaemic (n = 41), (3) without HIV (HIV-) and ID (n = 44) and (4) HIV- and iron-sufficient nonanaemic (n = 38). HIV+ children were virally suppressed (<50 HIV RNA copies/ml) on antiretroviral therapy (ART). Microbial composition of faecal samples (16S rRNA sequencing) and markers of gut inflammation (faecal calprotectin) and gut integrity (plasma intestinal fatty acid-binding protein [I-FABP]) were assessed.
RESULTS
Faecal calprotectin was higher in ID versus iron-sufficient nonanaemic children (p = 0.007). I-FABP did not significantly differ by HIV or iron status. ART-treated HIV (redundancy analysis [RDA] R
CONCLUSIONS
In our sample of 8- to 13-year-old virally suppressed HIV+ and HIV- children with or without ID, ID was associated with increased gut inflammation and changes in the relative abundance of specific microbiota. Moreover, in HIV+ children, ID had a cumulative effect that further shifted the gut microbiota to an unfavourable composition.
Substances chimiques
Iron
E1UOL152H7
RNA, Ribosomal, 16S
0
Leukocyte L1 Antigen Complex
0
Banques de données
ClinicalTrials.gov
['NCT03572010']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-832Informations de copyright
© 2023 The Authors. Journal of Human Nutrition and Dietetics published by John Wiley & Sons Ltd on behalf of British Dietetic Association.
Références
J Infect Dis. 2015 Jan 1;211(1):19-27
pubmed: 25057045
J Infect Dis. 2017 Sep 15;216(6):651-661
pubmed: 28934432
J Infect Dis. 2009 Apr 15;199(8):1177-85
pubmed: 19265479
Gut Microbes. 2014 Jul 1;5(4):562-70
pubmed: 25078714
Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):715-21
pubmed: 20823773
Arthritis Res Ther. 2019 Nov 27;21(1):248
pubmed: 31771630
Hematology Am Soc Hematol Educ Program. 2013;2013:377-81
pubmed: 24319207
AIDS. 2019 Apr 1;33(5):793-804
pubmed: 30649052
Curr Opin HIV AIDS. 2018 Jan;13(1):53-60
pubmed: 29028667
J Nutr. 2012 Feb;142(2):271-7
pubmed: 22190022
Microbiome. 2019 May 11;7(1):73
pubmed: 31078141
Sci Rep. 2021 Aug 5;11(1):15895
pubmed: 34354176
PLoS One. 2021 Oct 11;16(10):e0258226
pubmed: 34634074
Mucosal Immunol. 2012 Nov;5(6):646-57
pubmed: 22643849
Sci Rep. 2016 Aug 01;6:30673
pubmed: 27477587
PeerJ Comput Sci. 2023 Sep 1;9:e1516
pubmed: 37705656
J Hum Nutr Diet. 2023 Jun;36(3):819-832
pubmed: 36992541
Gastroenterol Hepatol (N Y). 2017 Jan;13(1):53-56
pubmed: 28420947
BMC Microbiol. 2021 Jan 6;21(1):11
pubmed: 33407128
mBio. 2015 Nov 17;6(6):e01453-15
pubmed: 26578675
J Infect Dis. 2018 Aug 24;218(7):1085-1089
pubmed: 29762690
Nutrients. 2021 Mar 16;13(3):
pubmed: 33809705
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
PLoS One. 2012;7(2):e30126
pubmed: 22319561
FEMS Microbiol Ecol. 2013 Jan;83(1):161-75
pubmed: 22845175
Sci Transl Med. 2013 Jul 10;5(193):193ra91
pubmed: 23843452
Therap Adv Gastroenterol. 2020 Nov 12;13:1756284820971202
pubmed: 33240394
J Int AIDS Soc. 2017 Mar 8;20(1):21526
pubmed: 28362071
PLoS Pathog. 2014 Feb 20;10(2):e1003829
pubmed: 24586144
Cell Host Microbe. 2013 Sep 11;14(3):329-39
pubmed: 24034618
Front Cell Infect Microbiol. 2021 Aug 30;11:734561
pubmed: 34527605
Ecol Food Nutr. 2021 Nov-Dec;60(6):707-721
pubmed: 33541138
Sci Rep. 2018 Sep 24;8(1):14277
pubmed: 30250162
Am J Clin Nutr. 2019 Aug 1;112(Suppl 1):458S-467S
pubmed: 32743650
Sci Rep. 2021 Apr 7;11(1):7666
pubmed: 33828220
Mucosal Immunol. 2015 Jul;8(4):760-72
pubmed: 25407519
Trends Microbiol. 2013 Jan;21(1):6-13
pubmed: 23062765
Sci Rep. 2017 Mar 06;7:43741
pubmed: 28262770
Sci Rep. 2018 Dec 5;8(1):17679
pubmed: 30518941
J Infect Dis. 2020 Jan 1;221(1):110-121
pubmed: 31504638
BMC Med. 2020 Feb 27;18(1):31
pubmed: 32102669
Bull World Health Organ. 2007 Sep;85(9):660-7
pubmed: 18026621
Clin Infect Dis. 2020 May 23;70(11):2413-2422
pubmed: 31260509
Nat Microbiol. 2022 Jan;7(1):132-144
pubmed: 34972822
J Acquir Immune Defic Syndr. 2016 May 1;72(1):15-20
pubmed: 26630672
Front Microbiol. 2019 May 22;10:1104
pubmed: 31191468
J Nutr. 2004 Nov;134(11):3127-32
pubmed: 15514286
Mucosal Immunol. 2017 Sep;10(5):1279-1293
pubmed: 28000678
J Infect Dis. 2020 Jan 14;221(3):483-492
pubmed: 31549151
Heliyon. 2021 Mar 10;7(3):e06432
pubmed: 33748490
Emerg Microbes Infect. 2018 Jun 22;7(1):113
pubmed: 29934497
Science. 2016 Apr 29;352(6285):560-4
pubmed: 27126039
AIDS Res Hum Retroviruses. 2014 Jun;30(6):514-22
pubmed: 24521167
Am J Gastroenterol. 2015 Jun;110(6):921-30
pubmed: 25986361
J Med Microbiol. 2009 May;58(Pt 5):535-545
pubmed: 19369513
N Engl J Med. 2019 Sep 19;381(12):1148-1157
pubmed: 31532961
Curr Opin HIV AIDS. 2018 Jan;13(1):73-80
pubmed: 29045252
J Cell Mol Med. 2018 Apr;22(4):2263-2271
pubmed: 29411528
AIDS. 2015 Nov 28;29(18):2409-18
pubmed: 26355675